Novartis AG enters its Q1 2026 earnings report with a consensus revenue estimate of $13.56 billion (+2.5% YoY) and an EPS expectation of $2.11 (-7.5% YoY), while the stock trades at $145.47, slightly above the $141.20 average analyst target.
The primary focus for investors is the impact of generic erosion on aging blockbusters like Entresto versus the performance of the company's new high-growth therapeutic engines.
Novartis is currently navigating the largest patent cliff in its history, anticipating a significant $4 billion headwind from generic competition throughout 2026. Offsetting this pressure, analysts are closely monitoring oncology blockbuster Kisqali, which is projected to deliver a substantial 54% revenue increase to $1.47 billion this quarter.